# Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

> **NCT06267144** · — · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Sintilimab plus chemotherapy

## Key facts

- **NCT ID:** NCT06267144
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-20
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-17
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06267144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06267144, "Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06267144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*